Clinical Trial Update: Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial update for Totum-63 (Valedia) assessing effects on glucose and lipid homeostasis in prediabetes and related metabolic conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertriglyceridemia
• Insulin Resistance
• Obesity
• Prediabetes
• Type 2 Diabetes Mellitus

Drugs mentioned

• Totum-63 (Totum-63)

Snippet

Sponsor: Valbiotis | Conditions: Prediabetes, Type 2 Diabetes | Phase 2, Phase 3 | Status: COMPLETED